The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global genitourinary drugs market size reached US$ 31.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 35.5 Billion by 2027, exhibiting a growth rate (CAGR) of 2.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.
The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on indication and product.
Breakup by Indication:
Breakup by Product:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Indication, Product, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at